Changes in plasma sclerostin level associated with use of a medium cut-off dialyzer in end-stage renal disease

다국어 초록 (Multilingual Abstract)

Background: Larger middle molecules are important substances associated with cardiovascular complications in end- stage renal disease. Unfortunately, larger middle molecules are not reliably removed by a high-flux dialyzer. A medium cut-off (MCO) membrane could effectively remove larger middle molecules. This study aimed to identify the long -term effect of the MCO membrane for changes of larger middle molecules.
Methods: Thirty-four patients were prospectively analyzed for 12 months. The enrolled patients were divided into control and MCO groups. We measured the plasma levels of growth differentiation factor 15, sclerostin, and fibroblast growth factor 23 in larger middle molecules and those of biomarkers including small solutes. Single-pool Kt/V (spKt/V) and reduction ratios also were evaluated.
Results: Plasma sclerostin did not increase significantly in patients using the MCO dialyzer (135.3 [–637.7 to 908.3], p = 0.715).
And there was a significant difference in change of plasma sclerostin level between the two groups (–1,646.9 [–3,015.2 to –278.7], p = 0.033). Furthermore, a negative association between calcium and sclerostin was not observed in the MCO group (r = –0.142, p = 0.587). Solute clearance of larger middle molecules in the MCO group was significantly higher. Moreover, spKt/V values for patients in the MCO group were significantly increased without albumin loss. Values are presented as mean (95% confidence interval [CI]) or adjusted mean (95% CI).
Conclusion: The MCO dialyzer can increase dialytic adequacy and suppress the increase in plasma sclerostin level without significant albumin loss in patients with end-stage renal disease.

참고문헌 (Reference)

1 Zeng C, "Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease" 15 : 99-105, 2018

2 Daugirdas JT, "Second generation logarithmic estimates of singlepool variable volume Kt/V : an analysis of error" 4 : 1205-1213, 1993

3 ScienceDirect, "Sclerostin: an overview"

4 Evenepoel P, "Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients" 100 : 4669-4676, 2015

5 Koos R, "Sclerostin as a potential novel biomarker for aortic valve calcification : an invivo and ex-vivo study" 22 : 317-325, 2013

6 Ward RA, "Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration" 69 : 1431-1437, 2006

7 Kim TH, "Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates : an observational prospective study" 21 : 2-, 2019

8 Fein PA, "Relationship of normalized protein catabolic rate with nutrition status and long-term survival in peritoneal dialysis patients" 31 : 45-48, 2015

9 김창성, "Relationship between serum uric acid and mortality among hemodialysis patients: Retrospective analysis of Korean end-stage renal disease registry data" 대한신장학회 36 (36): 368-376, 2017

10 Brandenburg VM, "Relationship between sclerostin and cardiovascular calcification in hemodialysis patients : a cross-sectional study" 14 : 219-, 2013

11 Pietrzyk B, "Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients" 51 : 519-526, 2019

12 Lim JH, "Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance hemodialysis patients" 10 : 7780-, 2020

13 Liabeuf S, "Plasma beta-2microglobulin is associated with cardiovascular disease in uremic patients" 82 : 1297-1303, 2012

14 Kirsch AH, "Performance of hemodialysis with novel medium cut-off dialyzers" 32 : 165-172, 2017

15 Bergström J, "No change in corrected beta 2-microglobulin concentration after cuprophane haemodialysis" 1 : 628-629, 1987

16 Glorieux G, "New uremic toxins : which solutes should be removed" 168 : 117-128, 2011

17 Zweigart C, "Medium cutoff membranes : closer to the natural kidney removal function" 40 : 328-334, 2017

18 Zickler D, "Medium cut-off(MCO)membranes reduce inflammation in chronic dialysis patients : a randomized controlled clinical trial" 12 : e0169024-, 2017

19 Maduell F, "Medium cut-off dialyzer versus eight hemodiafiltration dialyzers : comparison using a global removal score" 48 : 167-174, 2019

20 Cho NJ, "Long-term effect of medium cut-off dialyzer on middle uremic toxins and cell-free hemoglobin" 14 : e0220448-, 2019

21 Kim JK, "Leptin, pre-existing vascular disease, and increased arteriovenous fistula maturation failure in dialysis patients" 64 : 402-410, 2016

22 Drechsler C, "High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients : results from the NECOSAD study" 30 : 288-293, 2015

23 Ahmadmehrabi S, "Hemodialysis-induced cardiovascular disease" 31 : 258-267, 2018

24 Schwantes-An TH, "Fibroblast growth factor 23 genotype and cardiovascular disease in patients undergoing hemodialysis" 49 : 125-132, 2019

25 Wolley M, "Exploring the clinical relevance of providing increased removal of large middle molecules" 13 : 805-814, 2018

26 García-Prieto A, "Evaluation of the efficacy of a medium cut-off dialyser and comparison with other high-flux dialysers in conventional haemodialysis and online haemodiafiltration" 11 : 742-746, 2018

27 Kaynar K, "Evaluation of nutritional parameters of hemodialysis patients" 16 : 236-240, 2012

28 Kirsch AH, "Effects of hemodialysis therapy using dialyzers with medium cut-off membranes on middle molecules" 191 : 158-167, 2017

29 Marcio G, "Chronic kidney disease and risk factors responsible for sudden cardiac death: a whiff of hope?" 대한신장학회 35 (35): 3-9, 2016

30 London GM, "Bone-vascular cross-talk" 25 : 619-625, 2012

31 신민영, "Association between Growth Differentiation Factor 15 (GDF15) and Cardiovascular Risk in Patients with Newly Diagnosed Type 2 Diabetes Mellitus" 대한의학회 31 (31): 1413-1418, 2016

32 Krishnasamy R, "A trial evaluating mid cut-off value membrane clearance of albumin and light chains in hemodialysis patients : a safety device study" 49 : 468-478, 2020